Market Closed -
Nasdaq
04:00:00 2024-06-10 pm EDT
|
5-day change
|
1st Jan Change
|
2.89
USD
|
-3.99%
|
|
-5.25%
|
-33.10%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
37.62
|
21.66
|
35.59
|
18.99
|
226.4
|
157.7
|
-
|
-
|
Enterprise Value (EV)
1 |
37.62
|
21.66
|
35.59
|
18.99
|
226.4
|
157.7
|
157.7
|
157.7
|
P/E ratio
|
-3.46
x
|
-4.06
x
|
-7.77
x
|
-1.05
x
|
-5.47
x
|
-43
x
|
15.8
x
|
7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.7
x
|
0.43
x
|
0.6
x
|
0.35
x
|
2.8
x
|
1.49
x
|
1.3
x
|
1.16
x
|
EV / Revenue
|
0.7
x
|
0.43
x
|
0.6
x
|
0.35
x
|
2.8
x
|
1.49
x
|
1.3
x
|
1.16
x
|
EV / EBITDA
|
1,792
x
|
6.2
x
|
-
|
-
|
26
x
|
7.48
x
|
4.72
x
|
3.37
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
4.88
x
|
4.27
x
|
3.01
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
20.5%
|
23.4%
|
33.3%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
4,963
|
5,132
|
6,938
|
7,008
|
52,417
|
52,389
|
-
|
-
|
Reference price
2 |
7.580
|
4.220
|
5.130
|
2.710
|
4.320
|
3.010
|
3.010
|
3.010
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/24/22
|
3/31/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
53.94
|
50.82
|
59.03
|
54.13
|
80.75
|
106
|
121.1
|
135.9
|
EBITDA
1 |
0.021
|
3.493
|
-
|
-
|
8.711
|
21.08
|
33.4
|
46.76
|
EBIT
1 |
-5.274
|
-0.501
|
-0.201
|
-11.64
|
-1.932
|
4.96
|
19.32
|
32.76
|
Operating Margin
|
-9.78%
|
-0.99%
|
-0.34%
|
-21.5%
|
-2.39%
|
4.68%
|
15.95%
|
24.1%
|
Earnings before Tax (EBT)
1 |
-10.23
|
-5.407
|
-3.934
|
-18.08
|
-20.05
|
-8.046
|
13.65
|
35.36
|
Net income
1 |
-10.44
|
-5.339
|
-4.372
|
-18.11
|
-21.39
|
-3.44
|
10.44
|
23.93
|
Net margin
|
-19.36%
|
-10.51%
|
-7.41%
|
-33.45%
|
-26.49%
|
-3.24%
|
8.62%
|
17.61%
|
EPS
2 |
-2.190
|
-1.040
|
-0.6600
|
-2.590
|
-0.7900
|
-0.0700
|
0.1900
|
0.4300
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
32.34
|
36.92
|
52.46
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
30.51%
|
30.49%
|
38.6%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
153.44%
|
110.52%
|
112.19%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
353.78%
|
219.23%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/24/22
|
3/31/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
13.96
|
11.9
|
14.6
|
13.6
|
14.03
|
13.55
|
17.54
|
23.36
|
26.31
|
23.01
|
25.81
|
27.34
|
29.85
|
24.65
|
29.1
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-2.395
|
0.874
|
5.418
|
5.03
|
1.804
|
4.488
|
5.988
|
8.802
|
3.2
|
6.6
|
EBIT
1 |
-2.752
|
-4.147
|
-1.974
|
-3.411
|
-2.108
|
-3.302
|
-1.208
|
1.854
|
0.724
|
-2.302
|
0.6927
|
1.94
|
4.663
|
-
|
3.4
|
Operating Margin
|
-19.71%
|
-34.85%
|
-13.52%
|
-25.08%
|
-15.03%
|
-24.38%
|
-6.89%
|
7.94%
|
2.75%
|
-10%
|
2.68%
|
7.09%
|
15.62%
|
-
|
11.68%
|
Earnings before Tax (EBT)
1 |
-4.139
|
-5.955
|
-3.098
|
-5.245
|
-3.781
|
-4.968
|
-10
|
-1.301
|
-3.774
|
-6.283
|
-2.38
|
-1.16
|
1.776
|
-
|
-
|
Net income
1 |
-4.106
|
-5.955
|
-3.115
|
-5.257
|
-3.78
|
-4.982
|
-10.7
|
-1.93
|
-3.781
|
-6.251
|
-1.92
|
-0.673
|
2.05
|
-2.3
|
1.1
|
Net margin
|
-29.41%
|
-50.05%
|
-21.33%
|
-38.66%
|
-26.94%
|
-36.78%
|
-61%
|
-8.26%
|
-14.37%
|
-27.17%
|
-7.44%
|
-2.46%
|
6.87%
|
-9.33%
|
3.78%
|
EPS
2 |
-0.5900
|
-0.8500
|
-0.4500
|
-0.7500
|
-0.5400
|
-0.7100
|
-1.320
|
-0.0600
|
-0.0700
|
-0.1200
|
-0.0367
|
-0.0100
|
0.0367
|
-0.0250
|
0.0300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/9/22
|
7/27/22
|
11/14/22
|
3/31/23
|
5/15/23
|
8/10/23
|
10/26/23
|
3/7/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
32.3
|
36.9
|
52.5
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
0.3
|
0.32
|
0.33
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
0.28%
|
0.26%
|
0.24%
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/24/22
|
3/31/23
|
3/7/24
|
-
|
-
|
-
|
Last Close Price
3.01
USD Average target price
8
USD Spread / Average Target +165.78% Consensus |
1st Jan change
|
Capi.
|
---|
| -33.10% | 158M | | +0.82% | 91.94B | | -3.16% | 38.74B | | +64.83% | 26.66B | | -13.98% | 15.32B | | -5.40% | 13.3B | | -11.38% | 11.65B | | +156.85% | 10.37B | | -49.84% | 10.12B | | +2.32% | 9.06B |
Biopharmaceuticals
|